AAPL313.88+3.22 (+1.03%) ▲|ABBV252.90-1.76 (-0.69%) ▼|ABT95.12-0.72 (-0.75%) ▼|ACN137.19-4.96 (-3.49%) ▼|ADBE221.01-0.53 (-0.24%) ▼|AMAT570.53+16.03 (+2.89%) ▲|AMD517.41+1.30 (+0.25%) ▲|AMGN367.99-0.11 (-0.03%) ▼|AMT165.01-0.25 (-0.15%) ▼|AMZN243.62-2.36 (-0.96%) ▼|AVGO388.69+17.91 (+4.83%) ▲|AXP336.32-13.26 (-3.79%) ▼|BA224.83-6.85 (-2.96%) ▼|BAC58.32-1.55 (-2.58%) ▼|BKNG174.29-7.66 (-4.21%) ▼|BLK990.31-19.12 (-1.89%) ▼|BMY57.53-0.44 (-0.76%) ▼|BNY150.12-2.79 (-1.82%) ▼|BRK-B494.97-9.03 (-1.79%) ▼|C137.39-3.38 (-2.40%) ▼|CAT947.50+7.38 (+0.79%) ▲|CL93.04-1.99 (-2.09%) ▼|CMCSA23.19-0.22 (-0.94%) ▼|COF191.92-10.97 (-5.41%) ▼|COP110.70+2.26 (+2.08%) ▲|COST953.13+5.63 (+0.59%) ▲|CRM166.57-2.95 (-1.74%) ▼|CSCO113.82+2.03 (+1.82%) ▲|CVS104.44+0.11 (+0.11%) ▲|CVX175.92+1.91 (+1.10%) ▲|DE596.58-7.03 (-1.16%) ▼|DHR190.65-3.55 (-1.83%) ▼|DIS96.71-0.77 (-0.79%) ▼|DUK126.79-1.43 (-1.12%) ▼|EMR136.50-1.41 (-1.02%) ▼|FDX309.68-3.20 (-1.02%) ▼|GD374.32-0.32 (-0.09%) ▼|GE355.96-11.02 (-3.00%) ▼|GEV1,071.30-5.78 (-0.54%) ▼|GILD135.82-0.54 (-0.40%) ▼|GM76.23+0.20 (+0.26%) ▲|GOOG358.71-4.91 (-1.35%) ▼|GOOGL361.92-5.11 (-1.39%) ▼|GS1,029.18-13.81 (-1.32%) ▼|HD336.20-9.01 (-2.61%) ▼|HON220.36-4.69 (-2.08%) ▼|IBM301.92-4.21 (-1.38%) ▼|INTC110.24-0.15 (-0.14%) ▼|INTU272.10-9.07 (-3.23%) ▼|ISRG415.10-12.20 (-2.86%) ▼|JNJ263.35-3.89 (-1.46%) ▼|JPM330.52-8.70 (-2.56%) ▼|KO83.40-0.65 (-0.77%) ▼|LIN527.67-10.56 (-1.96%) ▼|LLY1,215.84-19.72 (-1.60%) ▼|LMT527.94-7.44 (-1.39%) ▼|LOW212.77-8.13 (-3.68%) ▼|LRCX333.15+7.02 (+2.15%) ▲|MA519.88-11.75 (-2.21%) ▼|MCD278.27-3.94 (-1.40%) ▼|MDLZ59.48-0.74 (-1.23%) ▼|MDT82.00-1.84 (-2.19%) ▼|META603.12-12.46 (-2.02%) ▼|MMM154.74-3.27 (-2.07%) ▼|MO72.79-0.17 (-0.23%) ▼|MRK125.99-2.87 (-2.23%) ▼|MS218.13-3.92 (-1.76%) ▼|MSFT383.34-5.50 (-1.41%) ▼|MU948.80+10.42 (+1.11%) ▲|NEE87.43-1.04 (-1.18%) ▼|NFLX75.59-0.59 (-0.77%) ▼|NKE42.88-0.33 (-0.76%) ▼|NOW107.78-2.96 (-2.67%) ▼|NVDA204.12+7.19 (+3.65%) ▲|ORCL140.57-1.04 (-0.73%) ▼|PEP142.50-2.49 (-1.71%) ▼|PFE24.04-0.03 (-0.12%) ▼|PG148.40-4.36 (-2.85%) ▼|PLTR132.22-2.15 (-1.60%) ▼|PM187.09-0.71 (-0.38%) ▼|QCOM186.56+3.59 (+1.96%) ▲|RTX194.90-5.96 (-2.96%) ▼|SBUX103.87+0.26 (+0.25%) ▲|SCHW101.69-0.24 (-0.24%) ▼|SO96.38-0.91 (-0.94%) ▼|SPG219.15-8.05 (-3.54%) ▼|T21.07-0.03 (-0.12%) ▼|TMO509.87-6.75 (-1.31%) ▼|TMUS180.14-4.59 (-2.48%) ▼|TSLA393.93-8.97 (-2.23%) ▼|TXN301.32+8.02 (+2.73%) ▲|UBER73.59-0.75 (-1.00%) ▼|UNH425.54-2.65 (-0.62%) ▼|UNP280.96-2.16 (-0.76%) ▼|UPS109.91-2.06 (-1.84%) ▼|USB60.99-1.90 (-3.02%) ▼|V347.52-4.68 (-1.33%) ▼|VZ42.45-0.14 (-0.33%) ▼|WFC85.57-1.61 (-1.85%) ▼|WMT113.10+1.56 (+1.40%) ▲|XOM140.95-0.75 (-0.53%) ▼|AAPL313.88+3.22 (+1.03%) ▲|ABBV252.90-1.76 (-0.69%) ▼|ABT95.12-0.72 (-0.75%) ▼|ACN137.19-4.96 (-3.49%) ▼|ADBE221.01-0.53 (-0.24%) ▼|AMAT570.53+16.03 (+2.89%) ▲|AMD517.41+1.30 (+0.25%) ▲|AMGN367.99-0.11 (-0.03%) ▼|AMT165.01-0.25 (-0.15%) ▼|AMZN243.62-2.36 (-0.96%) ▼|AVGO388.69+17.91 (+4.83%) ▲|AXP336.32-13.26 (-3.79%) ▼|BA224.83-6.85 (-2.96%) ▼|BAC58.32-1.55 (-2.58%) ▼|BKNG174.29-7.66 (-4.21%) ▼|BLK990.31-19.12 (-1.89%) ▼|BMY57.53-0.44 (-0.76%) ▼|BNY150.12-2.79 (-1.82%) ▼|BRK-B494.97-9.03 (-1.79%) ▼|C137.39-3.38 (-2.40%) ▼|CAT947.50+7.38 (+0.79%) ▲|CL93.04-1.99 (-2.09%) ▼|CMCSA23.19-0.22 (-0.94%) ▼|COF191.92-10.97 (-5.41%) ▼|COP110.70+2.26 (+2.08%) ▲|COST953.13+5.63 (+0.59%) ▲|CRM166.57-2.95 (-1.74%) ▼|CSCO113.82+2.03 (+1.82%) ▲|CVS104.44+0.11 (+0.11%) ▲|CVX175.92+1.91 (+1.10%) ▲|DE596.58-7.03 (-1.16%) ▼|DHR190.65-3.55 (-1.83%) ▼|DIS96.71-0.77 (-0.79%) ▼|DUK126.79-1.43 (-1.12%) ▼|EMR136.50-1.41 (-1.02%) ▼|FDX309.68-3.20 (-1.02%) ▼|GD374.32-0.32 (-0.09%) ▼|GE355.96-11.02 (-3.00%) ▼|GEV1,071.30-5.78 (-0.54%) ▼|GILD135.82-0.54 (-0.40%) ▼|GM76.23+0.20 (+0.26%) ▲|GOOG358.71-4.91 (-1.35%) ▼|GOOGL361.92-5.11 (-1.39%) ▼|GS1,029.18-13.81 (-1.32%) ▼|HD336.20-9.01 (-2.61%) ▼|HON220.36-4.69 (-2.08%) ▼|IBM301.92-4.21 (-1.38%) ▼|INTC110.24-0.15 (-0.14%) ▼|INTU272.10-9.07 (-3.23%) ▼|ISRG415.10-12.20 (-2.86%) ▼|JNJ263.35-3.89 (-1.46%) ▼|JPM330.52-8.70 (-2.56%) ▼|KO83.40-0.65 (-0.77%) ▼|LIN527.67-10.56 (-1.96%) ▼|LLY1,215.84-19.72 (-1.60%) ▼|LMT527.94-7.44 (-1.39%) ▼|LOW212.77-8.13 (-3.68%) ▼|LRCX333.15+7.02 (+2.15%) ▲|MA519.88-11.75 (-2.21%) ▼|MCD278.27-3.94 (-1.40%) ▼|MDLZ59.48-0.74 (-1.23%) ▼|MDT82.00-1.84 (-2.19%) ▼|META603.12-12.46 (-2.02%) ▼|MMM154.74-3.27 (-2.07%) ▼|MO72.79-0.17 (-0.23%) ▼|MRK125.99-2.87 (-2.23%) ▼|MS218.13-3.92 (-1.76%) ▼|MSFT383.34-5.50 (-1.41%) ▼|MU948.80+10.42 (+1.11%) ▲|NEE87.43-1.04 (-1.18%) ▼|NFLX75.59-0.59 (-0.77%) ▼|NKE42.88-0.33 (-0.76%) ▼|NOW107.78-2.96 (-2.67%) ▼|NVDA204.12+7.19 (+3.65%) ▲|ORCL140.57-1.04 (-0.73%) ▼|PEP142.50-2.49 (-1.71%) ▼|PFE24.04-0.03 (-0.12%) ▼|PG148.40-4.36 (-2.85%) ▼|PLTR132.22-2.15 (-1.60%) ▼|PM187.09-0.71 (-0.38%) ▼|QCOM186.56+3.59 (+1.96%) ▲|RTX194.90-5.96 (-2.96%) ▼|SBUX103.87+0.26 (+0.25%) ▲|SCHW101.69-0.24 (-0.24%) ▼|SO96.38-0.91 (-0.94%) ▼|SPG219.15-8.05 (-3.54%) ▼|T21.07-0.03 (-0.12%) ▼|TMO509.87-6.75 (-1.31%) ▼|TMUS180.14-4.59 (-2.48%) ▼|TSLA393.93-8.97 (-2.23%) ▼|TXN301.32+8.02 (+2.73%) ▲|UBER73.59-0.75 (-1.00%) ▼|UNH425.54-2.65 (-0.62%) ▼|UNP280.96-2.16 (-0.76%) ▼|UPS109.91-2.06 (-1.84%) ▼|USB60.99-1.90 (-3.02%) ▼|V347.52-4.68 (-1.33%) ▼|VZ42.45-0.14 (-0.33%) ▼|WFC85.57-1.61 (-1.85%) ▼|WMT113.10+1.56 (+1.40%) ▲|XOM140.95-0.75 (-0.53%) ▼|
30.4 C
New York
Wednesday, July 8, 2026

Tag: risk

newssourceFORcompanyinformationcontent1releasesmarket

2025 ICIS Top 100 Chemical Distributors Ranking Revealed

LONDON and NEW YORK, June 16, 2025 /PRNewswire/ -- Today, ICIS unveiled the 16th annual ICIS Top 100 Chemical Distributors, the most comprehensive global...

GETCHELL GOLD CORP. ANNOUNCES CLOSING OF UPSIZED $4 MILLION FINANCING AND CONVERSION OF FIRST TRANCHE OF DEBENTURES

VANCOUVER, BC, June 16, 2025 /CNW/ - Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce that...

Supersavers Risk Losing 401(k) Matches—Strategic Contribution Review Needed

Optimizing 401(k) Contributions: A Strategic Approach In the realm of disciplined investing, structured portfolio management, and dividend strategies, maximizing the utility of 401(k) plans is...

Ensuring Retirement Longevity: Evaluating Low-Risk Financial Strategies

**Ensuring Longevity of Your Retirement Portfolio: A Structured Approach** As a retired CFO with extensive experience in financial management, I approach retirement planning with a...

From Campus to Cockpit: Chula-Thai Airways Unite for a Future-Ready Thailand

BANGKOK, June 16, 2025 /PRNewswire/ -- Chulalongkorn University and Thai Airways International Public Company Limited have signed a memorandum of understanding (MoU) to promote and...

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  presented the subgroup analysis data from the Phase III COMPASSION-16...

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Readout – Prime Minister Carney meets with Prime Minister of the United Kingdom Sir Keir Starmer

OTTAWA, ON, June 15, 2025 /CNW/ - Today, the Prime Minister, Mark Carney, met with the Prime Minister of the United Kingdom (UK), Sir...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe jamais présentée

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRisk

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers